WallStSmart

Lineage, Inc. Common Stock (LINE)vsSachem Capital Corp (SACH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 27672% more annual revenue ($5.36B vs $19.28M). SACH leads profitability with a 32.7% profit margin vs -1.9%. SACH earns a higher WallStSmart Score of 54/100 (C-).

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 6.7Quality: 3.8
Piotroski: 5/9Altman Z: 0.81

SACH

Buy

54

out of 100

Grade: C-

Growth: 2.0Profit: 6.5Value: 8.0Quality: 4.0
Piotroski: 6/9Altman Z: 0.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LINEUndervalued (+75.9%)

Margin of Safety

+75.9%

Fair Value

$161.49

Current Price

$37.04

$124.45 discount

UndervaluedFair: $161.49Overvalued
SACHUndervalued (+80.0%)

Margin of Safety

+80.0%

Fair Value

$4.99

Current Price

$1.02

$3.97 discount

UndervaluedFair: $4.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

SACH4 strengths · Avg: 9.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Profit MarginProfitability
32.7%10/10

Keeps 33 of every $100 in revenue as profit

PEG RatioValuation
0.988/10

Growing faster than its price suggests

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Areas to Watch

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

SACH4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Market CapQuality
$48.93M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.5%3/10

ROE of 3.5% — below average capital efficiency

Debt/EquityHealth
1.663/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : SACH

The strongest argument for SACH centers on Price/Book, Profit Margin, PEG Ratio. Profitability is solid with margins at 32.7% and operating margin at 21.4%. PEG of 0.98 suggests the stock is reasonably priced for its growth.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Bear Case : SACH

The primary concerns for SACH are P/E Ratio, Market Cap, Return on Equity. Debt-to-equity of 1.66 is elevated, increasing financial risk.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while SACH is a declining play — different risk/reward profiles.

LINE is growing revenue faster at -0.2% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SACH scores higher overall (54/100 vs 36/100), backed by strong 32.7% margins. LINE offers better value entry with a 75.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.

Visit Website →

Sachem Capital Corp

REAL ESTATE · REIT - MORTGAGE · USA

Sachem Capital Corp. The company is headquartered in Branford, Connecticut.

Visit Website →

Want to dig deeper into these stocks?